Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Stock Transactions

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions.

Summary

• On May 31, 2024, Mark Dmytruk, the CFO of Ginkgo Bioworks Holdings, engaged in several transactions involving the company's stock.
• These transactions included the acquisition of Class A Common Stock through the vesting of Restricted Stock Units (RSUs).
• Dmytruk acquired 65,448 shares, 18,125 shares, and 22,917 shares of Class A Common Stock through RSU vesting.
• He also acquired 1,638 shares of Class A Common Stock through the conversion of Class B Common Stock.
• On June 3, 2024, Dmytruk disposed of 48,866 shares of Class A Common Stock at a price of $0.549 per share.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units.
• Following these transactions, Dmytruk directly owns 984,662 shares of Class A Common Stock.
• Dmytruk also holds 581,538, 598,125 and 1,031,250 Restricted Stock Units and 625,412 shares of Class B Common Stock subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions. The sale of shares to cover taxes is a common practice and doesn't necessarily reflect a negative outlook, but the low share price is a concern.

Positives

• The vesting of RSUs indicates that Dmytruk is meeting performance or time-based milestones set by the company.
• The conversion of Class B shares to Class A shares could be seen as a simplification of his holdings.

Negatives

• The sale of shares to cover tax obligations, while common, reduces Dmytruk's direct stake in the company.
• The sale of 48,866 shares of Class A Common Stock at $0.549 per share may be seen negatively.

Risks

• Continued sales of shares by insiders could create downward pressure on the stock price.
• The vesting schedule of RSUs and Class B shares could lead to further transactions in the future.

Future Outlook

The document does not contain specific forward-looking statements, but it implies continued vesting of RSUs and potential future conversions of Class B Common Stock.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The transactions themselves don't necessarily indicate a positive or negative outlook for the company, but the market may interpret them based on the overall trend of insider activity.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance in publicly listed companies like Ginkgo Bioworks.
• Similar transactions are regularly reported by executives at companies like Amyris, Zymergen (now Ginkgo Cell Engineering), and other synthetic biology firms.
• The scale of these transactions is typical for executive compensation packages involving stock and equity.

Stakeholder Impact

• Shareholders may be concerned about the sale of shares by a key executive, but it's important to consider the context of tax obligations.
• Employees holding RSUs will be interested in the vesting schedules and potential tax implications.

Key Dates